December 5, 2017 – Medication Assisted Treatment (MAT) has proven effective in treating the disease of addiction, and federal officials are encouraging more widespread use of MAT programming.
This week, the U.S. Food and Drug Administration approved Sublocade, a new monthly injection of buprenorphine (Suboxone) for patients to ease withdrawal symptoms, reports Newsweek. Unlike Vivitrol, Sublocade won’t require detoxification before the injection.
Malvern’s MAT program is highly structured, and the medication offered is only one aspect of the treatment protocol. Currently, MAT programs are available at both inpatient campuses in Malvern and Willow Grove, as well as outpatient locations in Trevose, Berwyn, and Cherry Hill.
From the report:
“It’s potentially a game changer,” Dr. Andrew Kolodny, co-director of opioid policy research at Brandeis University, told STAT. “This could become first-line [medication] for opioid addiction. It could open up opportunities for getting more patients buprenorphine.”
Individor, a London-based pharmaceuticals group, are the creators of the newly approved injectable product called Sublocade. In an FDA voting session, an overwhelming majority of the committee (18-1) supported the approval of Sublocade, Reuters reports.
Malvern Institute: We Give Hope
Read the full story on Newsweek.